Developmental and pharmacological regulation of apolipoprotein C-II gene expression - Comparison with apo C-I and apo C-III gene regulation

被引:34
作者
Andersson, Y
Majd, Z
Lefebvre, AM
Martin, G
Sechkin, AV
Kosykh, V
Fruchart, JC
Najib, J
Staels, B
机构
[1] Inst Pasteur, U325 INSERM, Dept Atherosclerose, F-59019 Lille, France
[2] Univ Lille 2, Fac Pharm, Lille, France
[3] Acad Med Sci, Cardiol Res Ctr, Moscow, Russia
[4] Moscow Coordinating Ctr Organ Donat, Moscow, Russia
关键词
apolipoproteins; gene regulation; hypolipidemic drugs; hypertriglyceridemia; lipoprotein metabolism;
D O I
10.1161/01.ATV.19.1.115
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increased plasma triglyceride concentrations are often observed in metabolic disorders predisposing to coronary heart disease. Among the major determinants of plasma triglyceride metabolism are the apolipoproteins (apos) of the C class, C-I, C-II, and C-m. Whereas physiological concentrations of apo C-II are required for lipolysis of triglycerides by Lipoprotein lipase (LPL), overexpression of all 3 C apolipoproteins leads to hypertriglyceridemia. Ln the present study, we investigated apo C-II gene regulation under conditions associated with profound changes in plasma triglyceride metabolism, ie, during postnatal development and after treatment with the triglyceride-lowering fibrate drugs, and compared its expression to that of apo C-I and apo C-m. Whereas the expression of both apo C-I and apo C-III is low in fetal liver, increases gradually after birth, and attains maximal levels after weaning, apo C-II gene expression is already detectable in the fetal liver, increases rapidly immediately after birth, and remains elevated throughout suckling. Thus, the increased ingestion of lipids during suckling is met by an earlier induction of apo C-II, the obligatory activator for LPL, compared with apo C-III and apo C-I, which antagonize triglyceride catabolism. Treatment of rats with fibrates decreased apo C-II gene expression in the liver, but not in the intestine, whereas apo C-I gene expression did not change. The decrease of liver apo C-II mRNA levels after fenofibrate occurred in a time- and dose-dependent manner and was reversible but appeared less pronounced than the decrease of apo C-III mRNA. Apo C-LT mRNA levels were not affected after treatment with BRL49653, a peroxisome proliferator-activated receptor (PPAR)gamma-specific ligand, suggesting that fibrates act on apo C-II expression via PPAR alpha. Addition of fenofibric acid to primary rat and human hepatocytes resulted in a decrease of apo C-II expression. In conclusion, fibrates decrease gene expression of apo C-II and apo C-m, but not apo C-I, in rat and human hepatocytes, This decrease of apo C-II and apo c-m gene expression, together with a lowered apo C-m to apo C-II. ratio, should result in an improved clearance of triglyceride-rich remnant lipoproteins from plasma, without hampering triglyceride lipolysis by LPL.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 51 条
[1]  
ANDERSSON Y, 1991, J LIPID RES, V32, P1805
[2]  
ANDERSSON Y, 1991, J BIOL CHEM, V266, P4074
[3]   HYPERTRIGLYCERIDEMIA ASSOCIATED WITH DEFICIENCY OF APOLIPOPROTEIN-C-II [J].
BRECKENRIDGE, WC ;
LITTLE, JA ;
STEINER, G ;
CHOW, A ;
POAPST, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (23) :1265-1273
[4]  
BURY J, 1986, J CLIN CHEM CLIN BIO, V24, P457
[5]   CHANGING RELATIVE PROPORTIONS OF APOLIPOPROTEINS-102 AND APOLIPOPROTEINS-103 OF VERY LOW-DENSITY LIPOPROTEINS IN HYPERTRIGLYCERIDEMIA [J].
CARLSON, LA ;
BALLANTYNE, D .
ATHEROSCLEROSIS, 1976, 23 (03) :563-568
[6]   INHERITANCE OF APOLIPOPROTEIN C-II DEFICIENCY WITH HYPERTRIGLYCERIDEMIA AND PANCREATITIS [J].
COX, DW ;
BRECKENRIDGE, WC ;
LITTLE, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (26) :1421-1424
[7]   The PPAR alpha-leukotriene B-4 pathway to inflammation control [J].
Devchand, PR ;
Keller, H ;
Peters, JM ;
Vazquez, M ;
Gonzalez, FJ ;
Wahli, W .
NATURE, 1996, 384 (6604) :39-43
[8]   AVAILABILITY OF APOLIPOPROTEIN CII IN RELATION TO THE MAXIMAL REMOVAL CAPACITY FOR AN INFUSED TRIGLYCERIDE EMULSION IN MAN [J].
ERKELENS, DW ;
BRUNZELL, JD ;
BIERMAN, EL .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1979, 28 (05) :495-501
[9]  
FOJO SS, 1992, CURRENT OPINION LIPI, V3, P186
[10]   REGULATION OF LIPOGENIC ENZYME GENE-EXPRESSION BY NUTRIENTS AND HORMONES [J].
GIRARD, J ;
PERDEREAU, D ;
FOUFELLE, F ;
PRIPBUUS, C ;
FERRE, P .
FASEB JOURNAL, 1994, 8 (01) :36-42